

Antifungal Drugs Market Growth Opportunity, Trend, Size, Major Companies, Forecast 2030 | Revenue \$25.0 Billion

Global Antifungal Drugs Market generated \$16.6 billion in 2020, and is projected to reach \$25.0 billion by 2030, witnessing a CAGR of 3.9% from 2021 to 2030.

PORTLAND, OREGON, UNITED STATES, July 21, 2022 /EINPresswire.com/ -- According to the report, the [Antifungal drugs market](#) size was valued at \$16.6 billion in 2020, and is estimated to reach \$25.0 billion by 2030, growing at a CAGR of 3.9% from 2021 to 2030..

The report provides an in-depth analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive scenario, and wavering market trends.



“

Rise in prevalence of chronic diseases such as diabetes, which causes fungal infection are expected to notably contribute toward the growth of the anti-fungal drugs market during the forecast period.”

Onkar Sumant

Antifungal drugs are medications that selectively eliminate fungal infections from the host. These fungal agents multiply by spreading spores that subsequently lead to infection on skin, hairs, vagina, and other body parts. The fungal infection causes candidiasis, fungal pneumonia, mucormycosis, and other diseases. The antifungal drugs market is continuously growing and evolving owing to robust developmental efforts made by researchers and market players in the field.

The surge in prevalence of fungal infections worldwide, increase in knowledge of myriad fungal infections among

populace, and rise in government funds to tackle antifungal diseases drive the growth of the global antifungal drugs market. Additionally, expiration of existing patents and rise in funding from public & private organizations would provide lucrative opportunities to emerging market

players in the near future. However, growth in population that possess antifungal drug resistance and side-effects associated with antifungal drugs hamper market growth.

Download Sample PDF at (Flash Sale Tell 20th August 2022):

<https://www.alliedmarketresearch.com/request-sample/2370>

Rise in incidences of fungal and nosocomial infections, surge in initiatives by public and private organizations to spread awareness about myriad of fungal infections, and growth in prevalence of fungal infections such as aspergillosis and candidiasis drive the growth of the global antifungal drugs market. Furthermore, upsurge in number of drug approvals provide lucrative opportunities for the expansion of the global anti-fungal drugs market during the forecast period.

COVID-19 scenario:

The outbreak of the COVID-19 pandemic led to have a positive impact on the growth of the global antifungal drugs market.

India contributed to approximately 71% of the global cases of mucormycosis in patients with COVID-19. Rise in cases of mucormycosis infectious disease had increased the usage of anti-fungal drugs.

The report offers detailed segmentation of the global antifungal drugs market based on drug class, infection type, therapeutic indications, dosage forms, and region.

Moreover, development of pharmaceutical industries and improvement in healthcare spending are anticipated to drive the growth of the anti-fungal drugs market. In addition, Fungal Genetic Resource of India (FUNGEN) was engaged in training graduate student mycologists in colleges and universities in isolation techniques, and operating on a crowdsourcing model with “mini-collections” developed at participating centers to provide awareness about fungus, the diseases caused by them, and the treatments. Hence, such robust initiatives taken by nongovernmental organizations are expected to fuel the market growth.

Asia-Pacific to grow at the fastest rate through 2030

Asia-Pacific is expected to register the highest growth rate of 4.5% CAGR throughout the forecast period, owing to the presence of countries with a high populace base, such as India and China, where the antifungal drug usage rate is on a rise due to the growing awareness about fungal infections among the common people and high prevalence of diseases.

For Purchase Enquiry at (Flash Sale Tell 20th August 2022):

<https://www.alliedmarketresearch.com/purchase-enquiry/2370>

Leading players of the global antifungal drugs market analyzed in the research include Pfizer Inc., Sanofi S.A., Gilead Sciences Inc., Merck & Co. Inc, Novartis AG, Abbott Laboratories., GlaxosmithKlinePlc, AstellasPharma Inc., Johnson & Johnson, and MerzPharma.

We also Offers Regional and Country Reports-

Japan Antifungal Drugs Market
South Korea Antifungal Drugs Market
Singapore Antifungal Drugs Market
China Antifungal Drugs Market
Indonesia Antifungal Drugs Market
Australia Antifungal Drugs Market
Taiwan Antifungal Drugs Market

Trending Reports in Healthcare Industry-

[Bone Grafts and Substitutes Market](#) - Global Opportunity Analysis and Industry Forecast, 2020-2030

[Preimplantation Genetics Diagnosis Market](#) - Global Opportunity Analysis and Industry Forecast, 2020-2030

"We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market."

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

David Correa
Allied Analytics LLP
800-792-5285
[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/582361754>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.